在肺癌化疗后,单一患者的艾滋病毒储量下降,这暗示了一种针对潜伏艾滋病毒的新方法。 A single patient’s HIV reservoirs dropped after chemotherapy for lung cancer, hinting at a new way to target dormant HIV.

约翰·霍普金斯的一项研究发现,化疗减少了一名患有肺癌和艾滋病毒的病人感染艾滋病毒的CD4+T细胞,从而提出了针对病毒持久性水库的潜在新战略。 A Johns Hopkins study found that chemotherapy reduced HIV-infected CD4+ T cells in a patient with both lung cancer and HIV, suggesting a potential new strategy to target the virus's persistent reservoirs. 使用帕利塔克斯和carboplatin的治疗导致血球膨胀的艾滋病毒感染细胞显著下降,这些细胞通常通过分裂而存活。 The treatment, using paclitaxel and carboplatin, led to a significant drop in clonally expanded, HIV-infected cells that normally survive by dividing. 实验室测试显示,除非这些细胞接受化疗或酸摩菲提尔,一种抗生殖药物,否则它们会增殖,这表明它们可能易受阻断快速细胞分裂的药物影响. Lab tests showed these cells proliferated unless exposed to chemotherapy or mycophenolate mofetil, an antiproliferative drug, indicating they may be vulnerable to drugs that halt rapid cell division. 调查结果虽然基于一个案例,但为在不需要恢复休眠病毒的情况下消除艾滋病毒储存库提供了一条有希望的道路,并计划进行进一步研究,以测试更广泛的适用性。 While based on a single case, the findings offer a promising path toward eliminating HIV reservoirs without needing to reactivate dormant virus, with further research planned to test broader applicability.